CVC Credit has announced its provision of debt facilities to facilitate the joint acquisition of Immedica Pharma by KKR and Impilo. Immedica, a prominent Swedish pharmaceutical company based in Stockholm, specializes in launching and commercializing drugs for rare and specialty diseases, particularly in areas such as genetic and metabolic disorders, hematology, oncology, and specialty care.

Founded in 2018, Immedica has demonstrated a strong track record of profitable growth and robust financial performance. The company boasts a comprehensive range of capabilities, including marketing, sales, compliance, pharmacovigilance, quality assurance, regulatory affairs, and market access. Its global distribution network serves patients across more than 50 countries in Europe, the Middle East, and North Africa.

Moris Nachmias, Managing Director at CVC Credit, expressed enthusiasm about supporting Immedica's ongoing expansion. He highlighted the company's impressive growth since its inception and the potential for future development. Simone Zacchi, a Partner at CVC Credit, noted the advantages of being part of the CVC Network, which allows their team to leverage insights from the Private Equity Healthcare team to enhance investment opportunities. Zacchi also mentioned the firm's ongoing partnership with KKR, having previously supported several of their acquisitions.

This acquisition aligns with CVC Credit's strategy of backing companies with strong growth potential in the healthcare sector. The collaboration with KKR and Impilo underscores CVC's commitment to investing in innovative healthcare solutions that address critical medical needs.

Overall, the acquisition of Immedica Pharma represents a significant move in the healthcare investment landscape, with CVC Credit playing a crucial role in financing this strategic partnership.